On Mar. 6, 2020, Cocrystal Pharma announced it had initiated its Coronavirus program. Cocrystal previously entered into a license agreement with Kansas State University Research Foundation (KSURF) to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat Norovirus and Coronavirus infections.